Financing - February 2, 2016
Vaccibody granted NOK 20 million
Vaccibody has received a grant up to NOK 20 million (USD 2.3 million) over four years from the Norwegian Research Council ‘s BIA Program to develop therapeutic cancer vaccines based on each patient’s specific neoantigens. Neoantigens are tumour- specific mutations in cancer cells. While most commonly shared tumour antigens used in cancer vaccines to date […]
Uncategorized - May 27, 2015
Fish Vaccine Grant Issued
The research collaboration “New Targeting Vaccines for Sustainable Aquaculture” has received a grant of NOK 10 million through the Norwegian Research Council’s program Biotek2021. The NOK 10 million will be awarded over three years. Oslo Cancer Cluster member Vaccibody is a partner in the project with the Norwegian Veterinary Institute, Pharmaq AS, Kjeller Innovasjon and […]
Financing - July 3, 2014
Vaccibody completes NOK 35 million financing
Norwegian company Vaccibody has through a new share issue completed a NOK 35 million financing. The financing comes from both existing and new investors. The largest new investor is represented by Datum and partners, which will take a seat in the Board of Directors. Arctic Securities is the manager for the share issue. According to Vaccibody, […]
